D-0083-2027 Class I Ongoing
FDA drug recall D-0083-2027 was initiated by Par Health USA, LLC on Oct 13, 2026 and is designated Class I. Reason for recall: Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution. The recall status is ongoing. Affected quantity: 1944 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 28, 2026
- Initiation Date
- Oct 13, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1944 vials
Product description
Argatroban Injection, USP, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Manufactured for: Endo USA, Malvern,PA 19355/ Argatroban Injection, 250 mg/2.5mL (100 mg/mL), 2.5 mL x 1 Single Dose Vial, Rx only, Distributed by: Par Pharmaceutical, Cranbury, NJ 08512, NDC 42023-182-89.
Reason for recall
Particulate matter: particulate matter identified as cellulose, polystyrene, polyethylene teraphalate, stainless steel, or stopper material in the product solution.
Distribution pattern
Nationwide within the United States
Code information
Lot #: 84193, Exp Date: 10/2026; 92880, Exp Date: 08/2027.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0083-2027
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026